Russia’s Sputnik V | Subject Expert Committee meets to consider grant emergency approval

The Subject Expert Committee (SEC) of the Indian drug regulator will meet today to consider granting emergency approval to Russia’s Covid-19 vaccine Sputnik V, as per the reports. Drugmaker Dr Reddy’s had last week submitted the safety and immunogenicity data the SEC had asked in the first meeting held on 24 February.

Dr Reddy’s had entered into a partnership with the Russian Direct Investment Fund to conduct clinical trials of Sputnik V. Dr Reddy’s had applied for emergency approval for Sputnik V. The company had conducted Phase 2 trials in India with around 1,500 participants. Phase 3 trials are still underway.